Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Breast06
CTR20254532Phase 3Active
- Sponsor
- AstraZeneca
- Start
- May 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of datopotamab deruxtecan in breast cancer, sponsored by AstraZeneca. Primary endpoint: Progression-free survival (PFS). Started May 2026; status: active.
02
Drugs
datopotamab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20254532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254532.